Journey Medical Corp has a consensus price target of $10.5, established from looking at the 8 latest analyst ratings. The last 3 analyst ratings were released from Alliance Global Partners, B. Riley Securities, and B. Riley Securities on February 16, 2024, September 7, 2023, and July 12, 2023. With an average price target of $6.83 between Alliance Global Partners, B. Riley Securities, and B. Riley Securities, there's an implied 82.22% upside for Journey Medical Corp from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
02/16/2024 | DERM | Buy Now | Journey Medical | $3.75 | 126.67% | Alliance Global Partners | Scott Henry | → $8.5 | Initiates | → Buy | Get Alert |
09/07/2023 | DERM | Buy Now | Journey Medical | $3.75 | 60% | B. Riley Securities | Kalpit Patel | → $6 | Reiterates | Buy → Buy | Get Alert |
07/12/2023 | DERM | Buy Now | Journey Medical | $3.75 | 60% | B. Riley Securities | Kalpit Patel | $3 → $6 | Maintains | Buy | Get Alert |
05/23/2023 | DERM | Buy Now | Journey Medical | $3.75 | -20% | B. Riley Securities | Kalpit Patel | $6 → $3 | Maintains | Buy | Get Alert |
03/30/2023 | DERM | Buy Now | Journey Medical | $3.75 | 60% | B. Riley Securities | Kalpit Patel | → $6 | Reiterates | → Buy | Get Alert |
02/25/2022 | DERM | Buy Now | Journey Medical | $3.75 | 140% | Cantor Fitzgerald | Brandon Folkes | → $9 | Initiates | → Overweight | Get Alert |
12/16/2021 | DERM | Buy Now | Journey Medical | $3.75 | 300% | Roth Capital | Scott Henry | — | Initiates | → Buy | Get Alert |
12/07/2021 | DERM | Buy Now | Journey Medical | $3.75 | 273.33% | B. Riley Securities | — | — | Initiates | → Buy | Get Alert |
The latest price target for Journey Medical (NASDAQ: DERM) was reported by Alliance Global Partners on February 16, 2024. The analyst firm set a price target for $8.50 expecting DERM to rise to within 12 months (a possible 118.51% upside). 5 analyst firms have reported ratings in the last year.
The latest analyst rating for Journey Medical (NASDAQ: DERM) was provided by Alliance Global Partners, and Journey Medical initiated their buy rating.
There is no last upgrade for Journey Medical.
There is no last downgrade for Journey Medical.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Journey Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Journey Medical was filed on February 16, 2024 so you should expect the next rating to be made available sometime around February 16, 2025.
While ratings are subjective and will change, the latest Journey Medical (DERM) rating was a initiated with a price target of $0.00 to $8.50. The current price Journey Medical (DERM) is trading at is $3.89, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.